Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.

16th September, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat. Ref.: Our intimation dated 7th March, 2025 - Completion of USFDA inspection at Alembic Pharmaceuticals Limited’s Bioequivalence Facility at Vadodara. We would like to inform the exchanges that the US Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) and has communicated the closure of inspection, which was carried out by them at the Company’s Bioequivalence Facility located at Vadodara, Gujarat, during 3rd March, 2025 to 7th March, 2025. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Chirag K. Shukla Company Secretary ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123